[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights",
    "summary": "Pfizer (PFE) closed the most recent trading day at $26.56, moving -0.67% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=cfafa4303d6398910ff88a781b522ca3c94870a0271a04d65288617ccf3dba35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735253120,
      "headline": "Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights",
      "id": 132168533,
      "image": "https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) closed the most recent trading day at $26.56, moving -0.67% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=cfafa4303d6398910ff88a781b522ca3c94870a0271a04d65288617ccf3dba35"
    }
  },
  {
    "ts": null,
    "headline": "AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC",
    "summary": "AstraZeneca and Daiichi Sankyo voluntarily withdraw regulatory filing for Dato-DXd in nonsquamous non-small cell lung cancer in the European Union.",
    "url": "https://finnhub.io/api/news?id=ff8ca95c9e03cfeeed4b109ad0c05bfc7ca123584979e7d8fa89da711d015eda",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735226340,
      "headline": "AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC",
      "id": 132165499,
      "image": "https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AstraZeneca and Daiichi Sankyo voluntarily withdraw regulatory filing for Dato-DXd in nonsquamous non-small cell lung cancer in the European Union.",
      "url": "https://finnhub.io/api/news?id=ff8ca95c9e03cfeeed4b109ad0c05bfc7ca123584979e7d8fa89da711d015eda"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Investing By Hand With Brian Bollinger And Rob Isbitts",
    "summary": "Rob Isbitts talks toÂ Brian Bollinger about their shared focus on dividend income using stocks like Verizon, Lowe's, McDonald's and Walgreens as examples.",
    "url": "https://finnhub.io/api/news?id=ee725e4f7ac7c1c115585eddb56a3cdbe6334e13ae55f0b7eb6dfe3bf131270b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735223400,
      "headline": "Dividend Investing By Hand With Brian Bollinger And Rob Isbitts",
      "id": 132166291,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Rob Isbitts talks toÂ Brian Bollinger about their shared focus on dividend income using stocks like Verizon, Lowe's, McDonald's and Walgreens as examples.",
      "url": "https://finnhub.io/api/news?id=ee725e4f7ac7c1c115585eddb56a3cdbe6334e13ae55f0b7eb6dfe3bf131270b"
    }
  },
  {
    "ts": null,
    "headline": "How To Build A Strategically Balanced $50,000 Dividend Portfolio To Be Well-Positioned For 2025",
    "summary": "Learn how to build a $50,000 dividend portfolio to position yourself well for 2025 with a focus on dividend income, growth, and diversification.",
    "url": "https://finnhub.io/api/news?id=9d183864ed70a18fc1686cc585a273143ae890c1b533464bb2dfd293fc385a66",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735221600,
      "headline": "How To Build A Strategically Balanced $50,000 Dividend Portfolio To Be Well-Positioned For 2025",
      "id": 132166149,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1249796169/image_1249796169.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Learn how to build a $50,000 dividend portfolio to position yourself well for 2025 with a focus on dividend income, growth, and diversification.",
      "url": "https://finnhub.io/api/news?id=9d183864ed70a18fc1686cc585a273143ae890c1b533464bb2dfd293fc385a66"
    }
  },
  {
    "ts": null,
    "headline": "PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr.",
    "summary": "This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, and Merck. Read more here.",
    "url": "https://finnhub.io/api/news?id=d9924bfb15be4a412c5d30ffc3c153fb65db609d6f0526759c3ece67141e5e6e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735205436,
      "headline": "PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr.",
      "id": 132164310,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/832255342/image_832255342.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, and Merck. Read more here.",
      "url": "https://finnhub.io/api/news?id=d9924bfb15be4a412c5d30ffc3c153fb65db609d6f0526759c3ece67141e5e6e"
    }
  },
  {
    "ts": null,
    "headline": "2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone",
    "summary": "Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.",
    "url": "https://finnhub.io/api/news?id=926999938b0fe33f3c1fc7c0ca1e5db52929e7393e238aee36c364dbfcb94eb1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735205400,
      "headline": "2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone",
      "id": 132164311,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.",
      "url": "https://finnhub.io/api/news?id=926999938b0fe33f3c1fc7c0ca1e5db52929e7393e238aee36c364dbfcb94eb1"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Harvesting Portfolio Week 199: $19,900 Allocated, $1,908.79 In Projected Dividends",
    "summary": "The Dividend Harvesting Portfolio remains profitable, despite recent declines, generating $1,908.79 in forward dividend income. Read what investors need to know.",
    "url": "https://finnhub.io/api/news?id=162af7b966cae7d533347e0fa5224c8d702a3bc8b9fe7601d996afe7655b6e89",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735203600,
      "headline": "Dividend Harvesting Portfolio Week 199: $19,900 Allocated, $1,908.79 In Projected Dividends",
      "id": 132164164,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The Dividend Harvesting Portfolio remains profitable, despite recent declines, generating $1,908.79 in forward dividend income. Read what investors need to know.",
      "url": "https://finnhub.io/api/news?id=162af7b966cae7d533347e0fa5224c8d702a3bc8b9fe7601d996afe7655b6e89"
    }
  },
  {
    "ts": null,
    "headline": "Kairos Pharma: Potential To Remove Resistance With Established Drugs",
    "summary": "Kairos Pharma's ENV-105 aims to overcome resistance in CRPC and EGFR-mutant NSCLC, with key data releases expected in 2025. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=13dd7bdadce638afc2bf7f47929662c415e77bfac121dca7c36221645b5869fb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735199509,
      "headline": "Kairos Pharma: Potential To Remove Resistance With Established Drugs",
      "id": 132163701,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962383/image_1386962383.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Kairos Pharma's ENV-105 aims to overcome resistance in CRPC and EGFR-mutant NSCLC, with key data releases expected in 2025. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=13dd7bdadce638afc2bf7f47929662c415e77bfac121dca7c36221645b5869fb"
    }
  }
]